EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

COVID ‐19 Vaccination During Pregnancy and Birth Defects: Results From the CDC COVID ‐19 Vaccine Pregnancy Registry, United States 2021–2022

Andrea J Sharma iD, Jennita Reefhuis, Lauren Head Zauche, Sabrina A Madni, Janet D Cragan, Cynthia A Moore iD, John F Nahabedian, Christine K Olson, CDC COVID‐19 Vaccine Pregnancy Registry team

Birth Defects Research · 2025-05 · 117 (5)

DOI: 10.1002/bdr2.2474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Birth Defects Research, online erschienen am 21.05.2025. Verfasst von Andrea J Sharma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, …. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Congenital Abnormalities, Vaccination. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CDC Operating Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We calculated prevalences of birth defects among infants of participants in the Centers for Disease Control and Prevention's (CDC) COVID‐19 Vaccine Pregnancy Registry (C19VPR).

Methods

C19VPR enrolled women receiving COVID‐19 vaccines ≤ 30 days before the last menstrual period or during pregnancy from December 2020 through June 2021. We included 19,931 participants with singleton pregnancies ending ≥ 20 weeks' gestation who did not report COVID‐19 illness during pregnancy. Clinicians identified birth defects from participant‐reported infant health information up to 4 months after birth. We compared C19VPR birth defect prevalences to published pre‐pandemic estimates. For seven defects originating during embryogenesis (cleft lip with/without cleft palate, atrial septal defect, coarctation of the aorta, ventricular septal defect, esophageal atresia or stenosis, hypospadias, kidney agenesis/hypoplasia/dysplasia), we estimated prevalence ratios comparing those vaccinated < 14 weeks' to those vaccinated ≥ 14 weeks' gestation.

Results

Participants reported receiving Pfizer‐BioNTech vaccines (59.0%), Moderna (38.2%), and Janssen (2.8%) vaccines. Most (65.2%) participants received their first COVID‐19 vaccine after the first trimester. The prevalence of major birth defects was 3.8%. Among defects with comparator estimates available ( n = 50), 35 were below or within expected ranges. C19VPR prevalences were higher than the comparator confidence interval for 15 defects; however, C19VPR confidence intervals included comparator estimates. Prevalences did not differ by the timing of vaccination for seven defects examined.

Conclusions

Birth defects prevalence estimates among infants born to women receiving COVID‐19 vaccines during or just prior to pregnancy were generally similar to pre‐pandemic estimates. While there was no strong evidence of associations between vaccination and specific defects, statistical power was low.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesCongenital AbnormalitiesVaccinationPregnancy Complications, InfectiousHumansFemalePregnancyUnited StatesRegistriesAdultSARS-CoV-2PrevalenceCenters for Disease Control and Prevention, U.S.Infant, NewbornYoung Adult

Stichwörter der Autor:innen

COVID‐19 vaccination in pregnancybirth defectscongenital anomaliespregnancyvaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • U.S. Public Health Service Commissioned Corps, Atlanta, Georgia, USA.
  • Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Goldbelt Professional Services LLC, Virginia, USA.
  • Eagle Global Scientific, LLC, Texas, USA.

ORCID-Profile: Andrea J Sharma, Cynthia A Moore

Förderung

  • CDC Operating Funds

Zitieren

APA

Sharma, A. J., Reefhuis, J., Zauche, L. H., Madni, S. A., Cragan, J. D., Moore, C. A., Nahabedian, J. F., Olson, C. K., & CDC COVID‐19 Vaccine Pregnancy Registry team (2025). COVID ‐19 Vaccination During Pregnancy and Birth Defects: Results From the CDC COVID ‐19 Vaccine Pregnancy Registry, United States 2021–2022. Birth Defects Research, 117(5). https://doi.org/10.1002/bdr2.2474

Vancouver

Sharma AJ, Reefhuis J, Zauche LH, Madni SA, Cragan JD, Moore CA, et al. COVID ‐19 Vaccination During Pregnancy and Birth Defects: Results From the CDC COVID ‐19 Vaccine Pregnancy Registry, United States 2021–2022. Birth Defects Research. 2025;117(5). doi:10.1002/bdr2.2474

BibTeX
@article{Sharma2025,
  author = {Sharma, Andrea J and Reefhuis, Jennita and Zauche, Lauren Head and Madni, Sabrina A and Cragan, Janet D and Moore, Cynthia A and Nahabedian, John F and Olson, Christine K and CDC COVID‐19 Vaccine Pregnancy Registry team, CDC COVID‐19 Vaccine Pregnancy Registry team},
  title = {COVID ‐19 Vaccination During Pregnancy and Birth Defects: Results From the CDC COVID ‐19 Vaccine Pregnancy Registry, United States 2021–2022},
  journal = {Birth Defects Research},
  year = {2025},
  volume = {117},
  number = {5},
  doi = {10.1002/bdr2.2474}
}
Kostenlos starten →